Abstract
ABSTRACTPurpose To investigate the course of anxiety and depression before and after transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and in the postoperative 1st month when the histopathological biopsy result was obtained.Methods In between June 2017- January 2019, 204 patients who underwent TRUS-Bx and completed the questionnaires assessing anxiety and depression were included in the study. Questionnaires were completed immediately before the biopsy, immediately after the biopsy and at the end of the first month when the histopathological biopsy results were given. State-Trait Anxiety Inventory (STAI), Hospital Anxiety and Depression Scale (HADS) and perceived stress scale (PSS) forms were used to assess anxiety and depression. After the histopathological examination patients were divided into two groups as patients without cancer (Group 1) and with cancer (Group 2). Data was compared between the groups.Results PSA level was negatively correlated with STAI TX-1 scores of the patients immediately after TRUS-Bx, whereas it was positively correlated with STAI TX-1 and TX-2 30 days after the TRUS-Bx. PSA level was positively correlated with HADS-A and HADS-D scores immediately before and 30 days after TRUS-Bx. Biopsy results showed a significant difference in 30 day post-biopsy related data. STAI TX-1, STAI TX-2, HADS-A, HADS-D and PSS scores were higher in Group 2 compared with Group 1.Conclusions Pre-biopsy anxiety disappeared after bx, but there was a significant increase in anxiety and depression in patients after the diagnosis of malignancy. Patients were seriously concerned about the diagnosis of prostate cancer.
Highlights
Through the widespread use of prostate-specific antigen (PSA), earlier detection of prostate cancer (PCa) at lower stages, lower grades, and smaller tumor volumes is feasible
We aimed to investigate the course of anxiety and depression before and after TRUS-Bx and to evaluate the factors that affect patient anxiety and depression
Correlation results between the questionnaire scores and the age, PSA level, and VAS scores are shown in Table-2
Summary
Through the widespread use of prostate-specific antigen (PSA), earlier detection of prostate cancer (PCa) at lower stages, lower grades, and smaller tumor volumes is feasible. Transrectal ultrasound-guided biopsy of the prostate (TRUS-Bx) is considered the standard of care for diagnosis of PCa. For men who have an elevated PSA test, histologic diagnosis of PCa requires TRUS-Bx, and the numbers of men undergoing biopsy have increased correspondingly [2]. Cancer-related worry or diagnosis of PCa and evidence of the psychological impact of biopsy can lead to increased anxiety and depression [5,6,7]. The high prevalence of severe distress after PCa diagnosis has resulted in the recommendation that interventions target treatment decision-related distress for all men and in-depth psychological support be offered for those who experience ongoing difficulties [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
